Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 46,470

Document Document Title
WO/2014/066318A1
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therape...  
WO/2014/065413A1
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/063199A1
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in...  
WO/2014/064258A1
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which i...  
WO/2014/064166A1
Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhib...  
WO/2014/065669A1
The invention relates to treatments for cognitive decline and/or memory impairment based on reducing the extracellular matrix in the hippocampus. Improved compositions are provided for such treatments. The invention also relates to detec...  
WO/2014/066132A1
The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -...  
WO/2014/065710A1
The invention relates to novel (3-arylsulfonyl-quinoline-8-yl)-dialkyl-amines of general formula 1, or pharmaceutically acceptable salts thereof, which are selective serotonin 5-HT6 receptor antagonists. The compounds can be used as a me...  
WO/2014/065606A1
The present invention provides a composition for preventing and treating nerve disease, comprising osmotin and an inhibitor for inhibiting activity or expression of gamma-aminobutyric acid (GABA) B receptor proteins so as to provide the ...  
WO/2014/066208A1
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effectiv...  
WO/2014/066695A1
Disclosed is a compound of formula (I). or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions including the compound of formula (I) and methods of using the compound of formula (I).  
WO/2014/066686A1
Provided are method of treatment with MANF. In certain embodiments, the invention provides a method of treating Parkinson's disease by administering MANF to the substantia nigra.  
WO/2014/064038A1
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula (I) as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are su...  
WO/2014/064162A1
Neprilysin inhibitors are described. The compounds or compositions containing them can be used as antidiarrheal agents, antisecretory agents, anxiolytic agents, antidepressants, cicatrizants, fluid effusion reducers or in the treatment o...  
WO/2014/060941A3
Disclosed are compounds of formula I, their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of...  
WO/2014/060394A1
The present invention relates to ethynyl derivatives of formula (I) or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It ha...  
WO/2014/062548A1
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the ...  
WO/2014/062870A3
A method of treating brain injury or brain trauma in an animal by administering to an animal TSG-6 protein or a biologically active fragment, derivative, or analogue thereof.  
WO/2014/061693A1
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...  
WO/2014/060509A1
The use of a bioactivated phytochemical is disclosed for preventing and treating neurodegenerative diseases, such as Parkinson's disease and multiple sclerosis. In particular, said bioactivated phytochemical is Rs-Glucoraphanin bioactiva...  
WO/2014/063071A1
Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50 200 IU, preferably 120 170 IU, more preferably 140 160 I...  
WO/2014/063057A1
The present invention provides a method for treating, alleviating, reversing or delaying progression of at least one symptom of Parkinson's Disease in a subject in need thereof by administering to the subject an effective amount of a 2-a...  
WO/2014/060386A1
The present invention provides compounds of formula (I), wherein Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture ...  
WO/2014/060384A1
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optic...  
WO/2014/060112A1
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060398A1
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its correspondin...  
WO/2014/060431A1
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositid...  
WO/2014/060501A1
The invention relates to an agent for treating migraines or migraine pain. The invention also relates to an agent for the preventative treatment of chronic migraines or chronic migraine pain. According to the invention, the agent contain...  
WO/2014/061676A1
Provided is a compound useful as a prophylactic or therapeutic agent for neurodegenerative diseases and others or a salt of the compound. The present invention relates to a compound represented by formula (I) [wherein each symbol is as d...  
WO/2014/060371A1
The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.  
WO/2014/059512A1
In an aspect, a formulation is provided that comprises at least one active substance and at least one coat comprising Eudragit E (dimethylaminoethyl methacrylate copolymer), wherein the formulation is free of any active substance externa...  
WO/2014/061764A1
A compound having an exceptional blood-sugar-reducing effect and represented by general formula (I), and a pharmaceutically acceptable salt thereof. In the formula, X is =C(R8)-, -CH(R8)-, =N-, or -O-; Y is =C(R9)-, -CH(R9)-, or =N-; Z i...  
WO/2014/062044A1
Invention is related to novel compounds - fluorinated benzenesulfonamides of general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...  
WO/2014/059558A1
The present invention provides a composition comprising nalbuphine prodrug-Sebacoyl dinalbuphine ester and pharmaceutical biodegradable polymer PLGA. The composition is prepared as a controlled release formulation, which can be implanted...  
WO/2014/059702A1
Disclosed are benfotiamine polymorphs, preparation method and use thereof. The crystal forms of benfotiamine are A crystal form benfotiamine, B crystal form benfotiamine, C crystal form benfotiamine, D crystal form benfotiamine or E crys...  
WO/2014/061735A1
 Provided is an improved β-subunit of human β-hexosaminidase, having activity derived from a α-subunit of wild-type human β-hexosaminidase, and having resistance to protease. A protein comprising, in the amino acid sequence for a...  
WO/2014/060113A1
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060432A1
New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositi...  
WO/2014/063087A1
A synergistic therapeutic effect is obtained in CNS cancer patients treated concomitantly with a first antineoplastic agent and a second antineoplastic agent, wherein one or both antineoplastic agents are administered by convection enhan...  
WO/2014/059383A1
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3a or GS...  
WO/2014/058736A1
The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the tre...  
WO/2014/057484A1
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X X 2 X 3 X 4 X, wherein X is a hydrophobic amino acid or threonine, X...  
WO/2014/057772A1
The present invention provides a novel method for treating Alzheimer's disease. A compound expressed by general formula (I) or a salt thereof.  
WO/2014/058742A1
This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment ...  
WO/2014/059295A1
Disclosed are methods and compositions for the treatment or prevention of vascular cognitive impairment. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (...  
WO/2014/059185A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, inde...  
WO/2014/059115A1
Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1.  
WO/2014/057179A1
The invention concerns a gaseous composition containing gaseous xenon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/059306A1
The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and/or anxiety.  
WO/2014/057995A1
The objective of the present invention is to provide an extract from inflamed rabbit skin inoculated with vaccinia virus and formulations, etc. including the extract which have greater uniformity in quality. By using the amount of N-acet...  

Matches 501 - 550 out of 46,470